Adaptimmune Therapeutics PLC – (ADAP) Stake Lowered by Vident Investment Advisory LLC

Share on StockTwits

Vident Investment Advisory LLC reduced its holdings in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 11.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 205,701 shares of the biotechnology company’s stock after selling 25,648 shares during the quarter. Vident Investment Advisory LLC owned about 0.22% of Adaptimmune Therapeutics worth $2,442,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. NEA Management Company LLC increased its stake in Adaptimmune Therapeutics by 10.9% in the 1st quarter. NEA Management Company LLC now owns 13,332,611 shares of the biotechnology company’s stock valued at $149,725,000 after purchasing an additional 1,306,612 shares in the last quarter. Millennium Management LLC increased its stake in Adaptimmune Therapeutics by 83.4% in the 1st quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock valued at $16,594,000 after purchasing an additional 672,046 shares in the last quarter. Baillie Gifford & Co. increased its stake in Adaptimmune Therapeutics by 33.6% in the 1st quarter. Baillie Gifford & Co. now owns 2,565,409 shares of the biotechnology company’s stock valued at $28,810,000 after purchasing an additional 644,816 shares in the last quarter. Dorsey Wright & Associates purchased a new position in Adaptimmune Therapeutics in the 2nd quarter valued at approximately $6,981,000. Finally, Foresite Capital Management II LLC purchased a new position in Adaptimmune Therapeutics in the 1st quarter valued at approximately $4,492,000. 59.32% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on the company. Leerink Swann raised their price objective on Adaptimmune Therapeutics to $20.00 and gave the company an “outperform” rating in a research note on Monday, June 4th. TheStreet downgraded Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, July 16th. Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 4th. Finally, ValuEngine raised Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 2nd. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.94.

Adaptimmune Therapeutics stock opened at $11.07 on Friday. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -13.84 and a beta of 1.09. Adaptimmune Therapeutics PLC – has a fifty-two week low of $6.60 and a fifty-two week high of $14.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $7.76 million. Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. sell-side analysts forecast that Adaptimmune Therapeutics PLC – will post -1.02 EPS for the current fiscal year.

In other Adaptimmune Therapeutics news, Director Ali Behbahani acquired 12,000,000 shares of the stock in a transaction dated Friday, September 7th. The stock was acquired at an average price of $1.67 per share, with a total value of $20,040,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Enterprise Associates 14 New acquired 3,000,000 shares of the stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, with a total value of $5,010,000.00. The disclosure for this purchase can be found here. Company insiders own 26.47% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC – (NASDAQ:ADAP).

Institutional Ownership by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply